Humacyte (HUMA) Cash from Investing Activities (2020 - 2026)
Humacyte (HUMA) posted quarterly Cash from Investing Activities of -$175000.0 for Q1 2026, up 23.25% year-over-year from -$141992.9 in Q1 2025, and down 348.72% quarter-over-quarter from -$39000.0 in Q4 2025.
Humacyte (HUMA) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Cash from Investing Activities for 7 consecutive years, with -$175000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 23.25% year-over-year to -$175000.0; the TTM figure through Mar 2026 stood at -$831000.0 (up 41.02% YoY), while the FY2025 annual figure was -$884000.0, up 43.77% from the prior year.
- Cash from Investing Activities fell to -$175000.0 in Q1 2026 per HUMA's latest filing, from -$39000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $5.2 million in Q4 2022 and bottomed at -$1.2 million in Q1 2023.
- Historically, Cash from Investing Activities has averaged $120058.8 across 5 years, with a median of -$175000.0 in 2026.
- On a YoY basis, Cash from Investing Activities climbed as much as 1310.45% in 2023 and fell as far as 5136.36% in 2023.
- Humacyte's Cash from Investing Activities stood at $5.2 million in 2022, then sank by 102.88% to -$150000.0 in 2023, then soared by 58.0% to -$63000.0 in 2024, then soared by 38.1% to -$39000.0 in 2025, then sank by 348.72% to -$175000.0 in 2026.
- Business Quant data shows HUMA's Cash from Investing Activities at -$175000.0 in Q1 2026, -$39000.0 in Q4 2025, and -$49000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Humacyte | 150.77 Mn | 150.77 Mn | -825,000.00 | -104,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -104,000.00 |
| Jun 30, 2026 | -104,000.00 |
| Mar 31, 2026 | -175,000.00 |
| Mar 31, 2026 | -175,000.00 |
| Dec 31, 2025 | -39,000.00 |
| Dec 31, 2025 | -39,000.00 |
| Sep 30, 2025 | -49,000.00 |
| Sep 30, 2025 | -49,000.00 |
| Jun 30, 2025 | -568,000.00 |
| Jun 30, 2025 | -568,000.00 |
| Mar 31, 2025 | -228,000.00 |
| Mar 31, 2025 | -228,000.00 |
| Dec 31, 2024 | -63,000.00 |
| Dec 31, 2024 | -63,000.00 |
| Sep 30, 2024 | -934,000.00 |
| Sep 30, 2024 | -934,000.00 |
| Jun 30, 2024 | -184,000.00 |
| Jun 30, 2024 | -184,000.00 |
| Mar 31, 2024 | -391,000.00 |
| Mar 31, 2024 | -391,000.00 |